Cancer Research Annual Meeting 2010 Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mandola, M. V.
Right arrow Articles by Ladner, R. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mandola, M. V.
Right arrow Articles by Ladner, R. D.
[Cancer Research 63, 2898-2904, June 1, 2003]
© 2003 American Association for Cancer Research

Molecular Biology and Genetics

A Novel Single Nucleotide Polymorphism within the 5' Tandem Repeat Polymorphism of the Thymidylate Synthase Gene Abolishes USF-1 Binding and Alters Transcriptional Activity

Michael V. Mandola, Jan Stoehlmacher, Susan Muller-Weeks, Gregory Cesarone, Mimi C. Yu, Heinz-Josef Lenz and Robert D. Ladner1

Department of Molecular Biology, The University of Medicine and Dentistry of New Jersey, School of Osteopathic Medicine, Stratford, New Jersey 08084 [M. V. M., S. M-W., G. C., R. D. L.], and Departments of Medical Oncology [J. S., H-J. L.] and Preventive Medicine [M. C. Y.], The University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, California 90033

Thymidylate synthase (TS) gene expression is modulated by a polymorphism in the 5' regulatory region of the gene. The polymorphism consists mainly of either two repeats (2R) or three repeats (3R) of a 28-bp sequence, yielding greater TS gene expression and protein levels with a 3R genotype. Two USF family E-box consensus elements are found within the tandem repeats of the 3R genotype, and one is found within the 2R genotype. These elements bind USF proteins in vitro by electrophoretic mobility shift analysis and in vivo by chromatin immunoprecipitation assay. We show that the additional USF consensus element within the 3R construct confers greater transcriptional activity relative to the 2R construct. Mutagenesis of the USF sites shows that the transcriptional regulation of TS is dependent, in part, on USF proteins binding within the tandem repeats. In addition, we identified a novel G->C single nucleotide polymorphism in the second repeat of 3R alleles within the USF consensus element that alters the ability of USF proteins to bind and thus alters the transcriptional activation of TS gene constructs bearing this genotype. Through RFLP analysis, we determined the respective frequencies of the C allele (3RC) among all 3R alleles in non-Hispanic whites, Hispanic whites, African Americans, and Singapore Chinese to be 56%, 47%, 28%, and 37%, respectively. Based on our findings, this novel single nucleotide polymorphism should be considered when the 5' tandem repeat polymorphism is being used as a predictor of clinical outcome to TS inhibitors.




This article has been cited by other articles:


Home page
 JCOHome page
E. Goekkurt, S.-E. Al-Batran, J. T. Hartmann, U. Mogck, G. Schuch, M. Kramer, E. Jaeger, C. Bokemeyer, G. Ehninger, and J. Stoehlmacher
Pharmacogenetic Analyses of a Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma With Fluorouracil and Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie
J. Clin. Oncol., June 10, 2009; 27(17): 2863 - 2873.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
G. Lurje, P. C. Manegold, Y. Ning, A. Pohl, W. Zhang, and H.-J. Lenz
Thymidylate synthase gene variations: predictive and prognostic markers
Mol. Cancer Ther., May 1, 2009; 8(5): 1000 - 1007.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
E. Goekkurt, S.-E. Al-Batran, U. Mogck, C. Pauligk, J. T. Hartmann, M. Kramer, E. Jaeger, G. Ehninger, and J. Stoehlmacher
Pharmacogenetic analyses of hematotoxicity in advanced gastric cancer patients receiving biweekly fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
Ann. Onc., March 1, 2009; 20(3): 481 - 485.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
P. M. Wilson, W. Fazzone, M. J. LaBonte, H.-J. Lenz, and R. D. Ladner
Regulation of human dUTPase gene expression and p53-mediated transcriptional repression in response to oxaliplatin-induced DNA damage
Nucleic Acids Res., January 1, 2009; 37(1): 78 - 95.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
M. Kajiwara, T. Terada, J.-i. Asaka, M. Aoki, T. Katsura, I. Ikai, and K.-i. Inui
Regulation of basal core promoter activity of human organic cation transporter 1 (OCT1/SLC22A1)
Am J Physiol Gastrointest Liver Physiol, December 1, 2008; 295(6): G1211 - G1216.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. D. Ricart, J. D. Berlin, K. P. Papadopoulos, S. Syed, D. W. Drolet, C. Quaratino-Baker, J. Horan, J. Chick, W. Vermeulen, A. W. Tolcher, et al.
Phase I, Pharmacokinetic and Biological Correlative Study of OSI-7904L, a Novel Liposomal Thymidylate Synthase Inhibitor, and Cisplatin in Patients with Solid Tumors
Clin. Cancer Res., December 1, 2008; 14(23): 7947 - 7955.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
B. R. Tan, W. S. Brenner, J. Picus, S. Marsh, F. Gao, C. Fournier, P. M. Fracasso, J. James, J. L. Yen-Revollo, and H. L. Mcleod
Phase I study of biweekly oxaliplatin, gemcitabine and capecitabine in patients with advanced upper gastrointestinal malignancies
Ann. Onc., October 1, 2008; 19(10): 1742 - 1748.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
P. M. Wilson, W. Fazzone, M. J. LaBonte, J. Deng, N. Neamati, and R. D. Ladner
Novel opportunities for thymidylate metabolism as a therapeutic target
Mol. Cancer Ther., September 1, 2008; 7(9): 3029 - 3037.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Dulucq, G. St-Onge, V. Gagne, M. Ansari, D. Sinnett, D. Labuda, A. Moghrabi, and M. Krajinovic
DNA variants in the dihydrofolate reductase gene and outcome in childhood ALL
Blood, April 1, 2008; 111(7): 3692 - 3700.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Sharma, J. M. Hoskins, L. P. Rivory, M. Zucknick, R. London, C. Liddle, and S. J. Clarke
Thymidylate Synthase and Methylenetetrahydrofolate Reductase Gene Polymorphisms and Toxicity to Capecitabine in Advanced Colorectal Cancer Patients
Clin. Cancer Res., February 1, 2008; 14(3): 817 - 825.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J.-i. Asaka, T. Terada, K. Ogasawara, T. Katsura, and K.-i. Inui
Characterization of the Basal Promoter Element of Human Organic Cation Transporter 2 Gene
J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 684 - 689.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Ruzzo, F. Graziano, F. Loupakis, E. Rulli, E. Canestrari, D. Santini, V. Catalano, R. Ficarelli, P. Maltese, R. Bisonni, et al.
Pharmacogenetic Profiling in Patients With Advanced Colorectal Cancer Treated With First-Line FOLFOX-4 Chemotherapy
J. Clin. Oncol., April 1, 2007; 25(10): 1247 - 1254.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S Popat, Z Chen, D Zhao, H Pan, N Hearle, I Chandler, Y Shao, W Aherne, and R. Houlston
A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer
Ann. Onc., December 1, 2006; 17(12): 1810 - 1817.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Largillier, M.-C. Etienne-Grimaldi, J.-L. Formento, J. Ciccolini, J.-F. Nebbia, A. Ginot, M. Francoual, N. Renee, J.-M. Ferrero, C. Foa, et al.
Pharmacogenetics of capecitabine in advanced breast cancer patients.
Clin. Cancer Res., September 15, 2006; 12(18): 5496 - 5502.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
R. A. Hubner, K. R. Muir, J.-F. Liu, G. S. Sellick, R. F.A. Logan, M. Grainge, N. Armitage, I. Chau, R. S. Houlston, and The United Kingdom Colorectal Adenoma Prevention C
Folate metabolism polymorphisms influence risk of colorectal adenoma recurrence.
Cancer Epidemiol. Biomarkers Prev., September 1, 2006; 15(9): 1607 - 1613.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
R. Pullmann Jr., K. Abdelmohsen, A. Lal, J. L. Martindale, R. D. Ladner, and M. Gorospe
Differential Stability of Thymidylate Synthase 3'-Untranslated Region Polymorphic Variants Regulated by AUF1
J. Biol. Chem., August 18, 2006; 281(33): 23456 - 23463.
[Abstract] [Full Text] [PDF]

Home page
 J BiochemHome page
C. Du, R. Niu, E. Chu, P. Zhang, and X. Lin
Sequence Analysis and Functional Study of Thymidylate Synthase from Zebrafish, Danio rerio.
J. Biochem., May 1, 2006; 139(5): 913 - 920.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Ruzzo, F. Graziano, K. Kawakami, G. Watanabe, D. Santini, V. Catalano, R. Bisonni, E. Canestrari, R. Ficarelli, E. T. Menichetti, et al.
Pharmacogenetic Profiling and Clinical Outcome of Patients With Advanced Gastric Cancer Treated With Palliative Chemotherapy
J. Clin. Oncol., April 20, 2006; 24(12): 1883 - 1891.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
S. Marsh and H. L. McLeod
Pharmacogenomics: from bedside to clinical practice.
Hum. Mol. Genet., April 15, 2006; 15(suppl_1): R89 - R93.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. Dotor, M. Cuatrecases, M. Martinez-Iniesta, M. Navarro, F. Vilardell, E. Guino, L. Pareja, A. Figueras, D. G. Mollevi, T. Serrano, et al.
Tumor Thymidylate Synthase 1494del6 Genotype As a Prognostic Factor in Colorectal Cancer Patients Receiving Fluorouracil-Based Adjuvant Treatment
J. Clin. Oncol., April 1, 2006; 24(10): 1603 - 1611.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. Graziano and K. Kawakami
Studying the Predictive/Prognostic Role of Thymidylate Synthase Genotypes in Patients With Colorectal Cancer: Is One Polymorphism Enough?
J. Clin. Oncol., October 1, 2005; 23(28): 7230 - 7231.
[Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
T. Ebersole, Y. Okamoto, V. N. Noskov, N. Kouprina, J.-H. Kim, S.-H. Leem, J. C. Barrett, H. Masumoto, and V. Larionov
Rapid generation of long synthetic tandem repeats and its application for analysis in human artificial chromosome formation
Nucleic Acids Res., September 1, 2005; 33(15): e130 - e130.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
W. Tan, X. Miao, L. Wang, C. Yu, P. Xiong, G. Liang, T. Sun, Y. Zhou, X. Zhang, H. Li, et al.
Significant increase in risk of gastroesophageal cancer is associated with interaction between promoter polymorphisms in thymidylate synthase and serum folate status
Carcinogenesis, August 1, 2005; 26(8): 1430 - 1435.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Kawakami, F. Graziano, G. Watanabe, A. Ruzzo, D. Santini, V. Catalano, R. Bisonni, F. Arduini, I. Bearzi, S. Cascinu, et al.
Prognostic Role of Thymidylate Synthase Polymorphisms in Gastric Cancer Patients Treated with Surgery and Adjuvant Chemotherapy
Clin. Cancer Res., May 15, 2005; 11(10): 3778 - 3783.
[Abstract] [Full Text] [PDF]

Home page
 INT J SURG PATHOLHome page
S. Popat, R. Wort, and R. S. Houlston
Relationship Between Thymidylate Synthase (TS) Genotype and TS Expression: A Tissue Microarray Analysis of Colorectal Cancers
International Journal of Surgical Pathology, April 1, 2005; 13(2): 127 - 133.
[Abstract] [PDF]

Home page
 Clin. Cancer Res.Home page
L. E. Carlini, N. J. Meropol, J. Bever, M. L. Andria, T. Hill, P. Gold, A. Rogatko, H. Wang, and R. L. Blanchard
UGT1A7 and UGT1A9 Polymorphisms Predict Response and Toxicity in Colorectal Cancer Patients Treated with Capecitabine/Irinotecan
Clin. Cancer Res., February 1, 2005; 11(3): 1226 - 1236.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
W. Lee, A. C. Lockhart, R. B. Kim, and M. L. Rothenberg
Cancer Pharmacogenomics: Powerful Tools in Cancer Chemotherapy and Drug Development
Oncologist, February 1, 2005; 10(2): 104 - 111.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
J. Chen, C. Kyte, W. Chan, J. G. Wetmur, C. S. Fuchs, and E. Giovannucci
Polymorphism in the Thymidylate Synthase Promoter Enhancer Region and Risk of Colorectal Adenomas
Cancer Epidemiol. Biomarkers Prev., December 1, 2004; 13(12): 2247 - 2250.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
J. Zhang, Y. Cui, G. Kuang, Y. Li, N. Wang, R. Wang, W. Guo, D. Wen, L. Wei, F. Yu, et al.
Association of the thymidylate synthase polymorphisms with esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma
Carcinogenesis, December 1, 2004; 25(12): 2479 - 2485.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Lecomte, J.-M. Ferraz, F. Zinzindohoue, M.-A. Loriot, D.-A. Tregouet, B. Landi, A. Berger, P.-H. Cugnenc, R. Jian, P. Beaune, et al.
Thymidylate Synthase Gene Polymorphism Predicts Toxicity in Colorectal Cancer Patients Receiving 5-Fluorouracil-based Chemotherapy
Clin. Cancer Res., September 1, 2004; 10(17): 5880 - 5888.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
D. Isla, C. Sarries, R. Rosell, G. Alonso, M. Domine, M. Taron, G. Lopez-Vivanco, C. Camps, M. Botia, L. Nunez, et al.
Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer
Ann. Onc., August 1, 2004; 15(8): 1194 - 1203.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
Y. Shin, I.-J. Kim, H. C. Kang, J.-H. Park, H.-R. Park, H.-W. Park, M. A. Park, J. S. Lee, K.-A. Yoon, J.-L. Ku, et al.
The E-cadherin -347G->GA promoter polymorphism and its effect on transcriptional regulation
Carcinogenesis, June 1, 2004; 25(6): 895 - 899.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.